NASDAQ:RGC Regencell Bioscience (RGC) Stock Price, News & Analysis $7.14 -0.21 (-2.87%) As of 01:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Regencell Bioscience Stock (NASDAQ:RGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Regencell Bioscience alerts:Sign Up Key Stats Today's Range$7.01▼$7.3550-Day Range$5.02▼$7.3552-Week Range$4.51▼$69.00Volume81,100 shsAverage Volume283,766 shsMarket Capitalization$3.53 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Regencell Bioscience Holdings Limited is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges. The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions. Regencell has also conducted research involving formulations for other health conditions, but its principal strategic focus has been on treatments for dementia and ADHD. These products remain investigational and are subject to clinical development and applicable regulatory requirements. Regencell was established in 2014 and is based in Hong Kong, where it conducts its research and development activities. The company is led by Yat-Gai Au, who serves as its chief executive officer and has been associated with Regencell’s development since its early operations. Regencell Bioscience Holdings Limited trades on the Nasdaq Capital Market under the symbol RGC.AI Generated. May Contain Errors. Read More Regencell Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreRGC MarketRank™: Regencell Bioscience scored higher than 6% of companies evaluated by MarketBeat, and ranked 866th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingRegencell Bioscience has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageRegencell Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Regencell Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioRegencell Bioscience has a P/B Ratio of 710.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.17% of the float of Regencell Bioscience has been sold short.Short Interest Ratio / Days to CoverRegencell Bioscience has a short interest ratio ("days to cover") of 3.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regencell Bioscience has recently decreased by 15.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRegencell Bioscience does not currently pay a dividend.Dividend GrowthRegencell Bioscience does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Regencell Bioscience this week, compared to 4 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Regencell Bioscience insiders have not sold or bought any company stock.Percentage Held by Institutions0.13% of the stock of Regencell Bioscience is held by institutions.Read more about Regencell Bioscience's insider trading history. Receive RGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Regencell Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RGC Stock News HeadlinesRegencell Bioscience (NASDAQ:RGC) Stock Jumps 0.3% - Time to Buy?October 1, 2026 | americanbankingnews.comRegencell Bioscience: I Got It Wrong (Rating Downgrade)September 23, 2026 | seekingalpha.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 7 at 1:00 AM | Chaikin Analytics (Ad)RGC Resources: More Likely To Appeal More To Income-Focused InvestorsAugust 18, 2026 | seekingalpha.comRegencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-KJuly 3, 2026 | theglobeandmail.comRegencell Bioscience surges on apparent short squeezeJuly 1, 2026 | msn.comRegencell Bioscience Holdings Limited (NASDAQ: RGC) Investors Have Until June 23, 2026 to Seek a Leadership Role in the Securities Class Action Lawsuit Contact Kaplan Fox ...June 30, 2026 | theglobeandmail.comPomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGCJune 23, 2026 | globenewswire.comSee More Headlines RGC Stock Analysis - Frequently Asked Questions How have RGC shares performed this year? Regencell Bioscience's stock was trading at $21.00 at the start of the year. Since then, RGC stock has decreased by 66.1% and is now trading at $7.1090. When did Regencell Bioscience's stock split? Regencell Bioscience's stock split on the morning of Monday, June 16th 2025.The 38-1 split was announced on Monday, June 2nd 2025. The newly minted shares were payable to shareholders after the market closes on Sunday, June 15th 2025. An investor that had 100 shares of stock prior to the split would have 3,800 shares after the split. When did Regencell Bioscience IPO? Regencell Bioscience (RGC) raised $22 million in an IPO on Wednesday, July 14th 2021. The company issued 2,300,000 shares at $8.50-$10.50 per share. How do I buy shares of Regencell Bioscience? Shares of RGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/07/2026Fiscal Year End6/30/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RGC Previous SymbolNASDAQ:RGC CIK1829667 Webregencellbioscience.com Phone852 2155 0823Fax852-2155-0853Employees10Year Founded2014Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.01 per share Price / Book710.90Miscellaneous Outstanding Shares494,490,000Free FloatN/AMarket Cap$3.52 billion OptionableN/A Beta1.18 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:RGC) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Regencell Bioscience Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Regencell Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
